Leadership Team

Our leadership team at LineaRx consists of visionary experts dedicated to advancing innovation and steering the company toward sustainable growth. Their leadership empowers our efforts, ensuring that we continue to push the boundaries of DNA-based therapies and make impactful progress in the field of genetic medicine.

Judy Murrah

Chairperson of the Board, President and Chief Executive Officer

Judy Murrah

Chairperson of the Board, President and Chief Executive Officer

Judith Murrah was appointed by the Board of Directors as Chairperson and Chief Executive Officer on June 18, 2025, and was appointed President in December 2024.

Murrah joined Applied DNA in 2013 as Chief Information Officer, and was later promoted to Chief Operating Officer in 2021. In 2017, she was also appointed Secretary of the Company.

Prior to 2013, Ms. Murrah was previously the Senior Director of Information Technology at Motorola Solutions, which had acquired her former firm, Symbol Technologies. Her role at Motorola Solutions included overseeing the global IT program management office, financial and supplier operations and quality assurance. At Symbol Technologies, Ms. Murrah held leadership positions in product line management, global account sales, corporate and marketing communications and IT.

Ms. Murrah holds an MBA from Harvard Business School, and a B.S. in Industrial Engineering from the University of Rhode Island. She is an inventor on 14 U.S. patents.

Beth Jantzen

Chief Financial Officer

Beth Jantzen

Chief Financial Officer

Prior to being appointed as Chief Financial Officer of Applied DNA Sciences, Ms. Jantzen was the Controller for the Company since May of 2013. Ms. Jantzen is a certified public accountant with over 15 years financial and accounting experience.

Prior to joining the Company Ms. Jantzen was a senior manager at Marcum LLP, since June 9, 2014, where she managed multiple engagements and specialized in SEC policies, practices and procedures, including Sarbanes-Oxley compliance as well as valuations involving acquisitions. Ms Jantzen was named Who’s Who in Accounting/Audits by Long Island Business News in 2012.

Clay Shorrock, Esq.

Chief Legal Officer, Executive Director, Business Development and President of LineaRx, Inc.,

Clay Shorrock, Esq.

Chief Legal Officer, Executive Director, Business Development and President of LineaRx, Inc.,

Clay Shorrock serves on the executive leadership team as Chief Legal Officer and Executive Director, Business Development and President of LineaRx, Inc. In this role, Mr. Shorrock leads Applied DNA’s legal, regulatory, IP, and business development functions.

Mr. Shorrock has over a decade of experience in intellectual property, patent law, and complex commercial transactions having represented clients, including Fortune 500 and development stage companies. He holds extensive legal experience in the areas of biotechnology, molecular biology, immunotherapy, and medical diagnostics. Prior to his current role, Mr. Shorrock served as general and IP counsel to Applied DNA from 2016 through 2021. Mr. Shorrock holds a B.A. in Biology from Franklin and Marshall College and a J.D. with a concentration in intellectual property from Seton Hall University Law School.